BioCentury
ARTICLE | Company News

QLT, Advanced Ocular deal

May 29, 2006 7:00 AM UTC

QLT received an exclusive option to license AOS’s rapamycin-based technology to treat ophthalmic diseases. If QLT exercises the option, AOS will receive up to $3.5 million in option fees and milestone...